[1] Kalia, L.V. and Lang, A.E. (2015) Parkinson’s Disease. Lancet, 386, 896-912.
https://doi.org/10.1016/S0140-6736(14)61393-3
[2] Nutt, J.G. (2008) Pharmacokinetics and Pharmacodynamics of Levodopa. Move-ment Disorders, 23, S580-S584.
https://doi.org/10.1002/mds.22037
[3] Griffiths, R.I., Kotschet, K., Arfon, S., et al. (2012) Automated Assessment of Brady-kinesia and Dyskinesia in Parkinson’s Disease. J Parkinsons Dis, 2, 47-55.
[4] Bergquist, F. and Horne, M. (2014) Can Objective Measurements Improve Treat-ment Outcomes in Parkinson’s Disease? European Neurological Review, 9, 27-30.
https://doi.org/10.17925/ENR.2014.09.01.27
[5] Horne, M.K., McGregor, S. and Bergquist, F. (2015) An Objective Fluctuation Score for Parkinson’s Disease. PLoS ONE, 10, e0124522.
https://doi.org/10.1371/journal.pone.0124522
[6] Postuma, R.B., Berg, D., Stern, M., et al. (2015) MDS Clinical Diagnostic Criteria for Parkinson’s Disease. Movement Disorders, 30, 1591-1599.
https://doi.org/10.1002/mds.26424
[7] Kempster, P.A., Williams, D.R., Selikhova, M., Holton, J., Revesz, T. and Lees, A.J. (2007) Patterns of Levodopa Response in Parkinson’s Disease: A Clinico-Patho-logical Study. Brain, 130, 2123-2128.
https://doi.org/10.1093/brain/awm142
[8] Papapetropoulos, S. and Mash, D.C. (2007) Motor Fluctuations and Dyskinesias in Advanced/End Stage Parkinson’s Disease: A Study from a Population of Brain Do-nors. Journal of Neural Transmission, 114, 341-345.
https://doi.org/10.1007/s00702-006-0603-6
[9] Coelho, M., Marti, M.J., Tolosa, E., et al. (2010) Late-Stage Parkinson’s Disease: The Barcelona and Lisbon Cohort. Journal of Neurology, 257, 1524-1532.
https://doi.org/10.1007/s00415-010-5566-8
[10] Connolly, B.S. and Lang, A.E. (2014) Pharmacological Treatment of Parkinson Di-sease. A Review. JAMA, 311, 1670-1683.
https://doi.org/10.1001/jama.2014.3654
[11] Fabbri, M., Coelho, M., Abreu, D., et al. (2016) Do Patients with Late-Stage Parkin-son’s Disease Still Respond to Levodopa? Parkinsonism & Related Disorders, 26, 10-16.
https://doi.org/10.1016/j.parkreldis.2016.02.021
[12] Coelho, M., Marti, M.J., Sampaio, C., et al. (2015) Dementia and Severity of Parkin-sonism Determines the Handicap of Patients in Late-Stage Parkinson’s Disease: The Barcelona-Lisbon Cohort. European Journal of Neurology, 22, 305-312.
https://doi.org/10.1111/ene.12567
[13] Hand, A., Gray, W.K., Oates, L.L., et al. (2016) Medication Use in People with Late Stage Parkinson’s Disease and Parkinsonism Living at Home and in Institutional Care in North-East England: A Balance of Symptoms and Side-Effects? Parkin-sonism & Related Disorders, 32, 120-123.
https://doi.org/10.1016/j.parkreldis.2016.09.001